TNDM
Tandem Diabetes Care, Inc.
Is TNDM Halal?
Insulin-pump and diabetes-management devices are permissible healthcare products, but current debt/assets and liquidity/assets fail the examined asset-based screens.
What You Should Know
Tandem Diabetes Care, Inc. designs and sells insulin-delivery systems including t:slim X2 and Mobi pumps and related software. Its March 31, 2026 Form 10-Q reports $1,153.394 million of assets, $601.768 million of convertible debt, $179.325 million of cash, $390.931 million of short-term investments, $140.672 million of accounts receivable and $247.221 million of first-quarter revenue. Debt/assets is 52.17%, liquidity/assets is 49.44% and receivables-plus-cash/assets is 27.74%; gross interest income is not separately disclosed. The medical-device activity is generally permissible, but the current quantitative result is doubtful.
⚠️ Concerns
- •Debt/assets is 52.17%, above the examined 33.333% asset-based limit
- •Liquidity/assets is 49.44%, above the examined asset-based limit
- •Convertible debt and short-term investments are material
- •Gross interest income is unavailable; no purification amount is inferred
- •Re-screen after debt paydown, refinancing or a new filing
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-15.
601.768 / 1,153.394
570.256 / 1,153.394
319.997 / 1,153.394
- Financial
- Fails
- Overall
- Fails
Debt/assets is 52.17% and liquidity/assets is 49.44%, above the examined 33.333% limits; receivables plus cash/assets is 27.74%.
- Financial
- Fails
- Overall
- Fails
Debt/assets is 52.17% and liquidity/assets is 49.44%, above the examined MSCI 33.33% limits; receivables plus cash/assets is 27.74%.
- Financial
- Fails
- Overall
- Fails
Debt/assets is 52.17% and liquidity/assets is 49.44%, above the examined Malaysia SAC limits; this is not an official classification.
- Financial
- Not calculated
- Overall
- Fails
A licensed historical market-cap series is not stored; the asset-based screens fail on debt and liquidity.
Business-activity disclosure
Tandem designs and sells insulin pumps, diabetes-management systems and related software. Healthcare devices are generally permissible, while product, customer and end-use disclosure remains methodology-dependent.
Limitation: The filing does not allocate every product, customer or end use into a universal prohibited-activity numerator, and gross interest income is unavailable.
Purification
Gross interest income is unavailable and no purification amount is inferred from net investment-income amortization.
Inputs, assumptions and primary sources
- Amounts are USD millions from Tandem Diabetes Care's March 31, 2026 Form 10-Q.
- Debt is $601.768 million of noncurrent convertible debt; operating leases are excluded.
- Cash and cash equivalents are $179.325 million. Short-term available-for-sale investments are $390.931 million and are included as identifiable interest-bearing securities.
- Accounts receivable, net is $140.672 million and first-quarter revenue is $247.221 million.
- Gross interest income is not separately disclosed; net investment-income amortization is not substituted, and the filing does not provide a universal prohibited-revenue numerator.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →